VEGFA and hepatocellular carcinoma: The IMbrave150 trial is a phase III clinical trial in which advanced HCC patients previously untreated were randomized to receive the combination of the anti-PD-L1 atezolizumab plus the anti-VEGF bevacizumab (atezo+beva) or sorafenib in a 2:1 ratio [7].